(Amendment No. 21)
If the filing person
has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing
this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box
☐
.
The information required
on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities
Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject
to all other provisions of the Act (however, see the Notes).
CUSIP No. 23323G106
|
Schedule 13D/A
|
Page 2 of 6
|
1
|
NAMES OF REPORTING PERSONS
Dr. L. S. Smith
|
2
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)
|
(a)
☐
(b)
☐
|
3
|
SEC USE ONLY
|
4
|
SOURCE OF FUNDS (see instructions)
N/A
|
5
|
CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) or 2 (e)
|
☐
|
6
|
CITIZENSHIP OR PLACE OF ORGANIZATION
United States
|
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
|
7
|
SOLE VOTING POWER
1,501,527
|
8
|
SHARED VOTING POWER
0
|
9
|
SOLE DISPOSITIVE POWER
1,501,527
|
10
|
SHARED DISPOSITIVE POWER
0
|
11
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,501,527
|
12
|
CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)
|
☐
|
13
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
12.3%
|
14.
|
TYPE OF REPORTING PERSON (see instructions)
IN
|
|
|
|
|
|
CUSIP No. 23323G106
|
Schedule 13D/A
|
Page 3 of 6
|
Item 1. Security and Issuer.
This statement relates to the common stock, par value $0.01
per share (the “
Common Stock
”), of DGSE Companies, Inc., a Nevada corporation (the “
Issuer
”),
whose principal executive office is located at 15850 Dallas Parkway, Suite 140, Dallas, Texas 75248.
Item 2. Identity and Background.
(a) Dr. L. S. Smith, an individual (“
Dr. Smith
”).
(b) 519 Interstate 30, Suite 243, Rockwall, Texas 75087.
(c) Not applicable.
(d) During the last five years, Dr. Smith has not been convicted
in a criminal proceeding (excluding traffic violations or similar misdemeanors).
(e) Dr. Smith has not, during the last five years, been a
party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in or was subject to
(i) a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal
or state securities laws; or (ii) a finding of any violation with respect to such laws.
(f) Dr. Smith is a citizen of the United States.
Item 3. Source and Amount of Funds or Other Consideration.
Not applicable.
Item 4. Purpose of Transaction.
Not applicable.
Item 5. Interest in Securities of Issuer.
(a) As of the date of this report, Dr. Smith beneficially
owns 1,501,527 shares of the Issuer’s Common Stock, which, in the aggregate, represents 12.3% of the currently outstanding
shares of the Issuer’s Common Stock. The foregoing calculation of percentage ownership is based on 12,203,584 shares of Common
Stock outstanding, as reported in the Issuer’s most recent Form 10-Q filed May 14, 2014.
(b) Dr. Smith has the sole power to vote or to direct the
vote and sole power to dispose or direct the disposition with respect to 1,501,527
shares of the Issuer’s Common Stock.
(c) Not applicable.
(d) Dr. Smith confirms that he is not aware of any other
person with the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any of
the shares of common stock of the Issuer beneficially owned by him.
(e) Not applicable.
CUSIP No. 23323G106
|
Schedule 13D/A
|
Page 4 of 6
|
Item 6. Contracts, Arrangements, Understandings or Relationships
With Respect to Securities of the Issuer.
Pursuant to the terms of that certain Agreement to Execute Smith
Irrevocable Proxy, dated May 25, 2010, by and between NTR Metals, LLC, a Texas limited liability company (“
NTR
”),
and Dr. Smith, attached hereto as
Exhibit 99.1
, Dr. Smith delivered to NTR that certain Smith Irrevocable Proxy to Vote,
by and between NTR and Dr. Smith, in the form attached hereto as
Exhibit 99.2
(the “
Smith Proxy
”), whereby
Dr. Smith granted NTR the power to vote all of the shares of Common Stock owned by Dr. Smith as well as all of those shares of
Common Stock over which Dr. Smith held a proxy. This Schedule 13D/A is filed to reflect the expiration of the Smith Proxy. As a
result of the expiration of the Smith Proxy, NTR no longer holds the power to vote any of the shares included therein.
Item 7. Materials to be Filed as Exhibits.
99.1 Agreement to Execute Smith Irrevocable Proxy, dated
as of May 25, 2010, executed by Dr. L. S. Smith in favor of NTR Metals, LLC (previously filed as Exhibit 99.6 to the Schedule 13D
of NTR Metals, LLC filed on June 1, 2010)
99.2 Smith Irrevocable Proxy to Vote (previously filed as
Exhibit 99.3 to the Current Report on Form 8-K of the Issuer filed on November 15, 2011)
CUSIP No. 23323G106
|
Schedule 13D/A
|
Page 5 of 6
|
EXHIBITS
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Agreement to Execute Smith Irrevocable Proxy, dated as of May 25, 2010, executed by Dr. L. S. Smith in favor of NTR Metals, LLC (previously filed as Exhibit 99.6 to the Schedule 13D of NTR Metals, LLC filed on June 1, 2010)
|
|
|
|
99.2
|
|
Smith Irrevocable Proxy to Vote (previously filed as Exhibit 99.3 to the Current Report on Form 8-K of the Issuer filed on November 15, 2011)
|
CUSIP No. 23323G106
|
Schedule 13D/A
|
Page 6 of 6
|
SIGNATURES
After reasonable inquiry and to the best
of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
|
Dr. L. S. Smith
|
|
|
|
|
|
/s/ Dr. L. S. Smith
|
|
Dr. L. S. Smith
|
|
|
Date: May 28, 2014
|
|